What are Castle Biosciences's total assets?

Castle Biosciences (CSTL) holds $547.8M in total assets, up 9.2% year over year.

How much debt does Castle Biosciences have?

Castle Biosciences carries $36.7M in total debt against $461.4M of shareholders' equity, a debt-to-equity ratio of 0.08.

How much cash does Castle Biosciences have?

Castle Biosciences holds $63.8M in cash and equivalents.

Can Castle Biosciences cover its short-term obligations?

Its current ratio is 6.75 — current assets exceed current liabilities.

Where does Castle Biosciences's balance sheet data come from?

Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Castle Biosciences CSTL Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$63.76M-28.9%	$116.73M-2.5%	$85.56M-9.9%	$82.23M-3.9%	$89.69M+8.1%
Short-term investments	$5.6M-96.9%	$5.59M—	$5.58M-97.0%	$184.81M+6.1%	$183.33M+17.3%
Accounts receivable, net	$42.26M-25.0%	$43.38M-15.3%	$49.48M-1.5%	$52.31M+13.7%	$56.35M+32.0%
Inventories	$10.46M+52.7%	$10.25M+26.0%	$8.65M+31.6%	$8.37M+4.4%	$6.85M-10.4%
Prepaid expenses and other current assets	$14.49M+31.3%	$7.96M+3.7%	$11.9M+45.9%	$12.06M+79.6%	$11.04M+77.4%
Total current assets	$328.9M-5.9%	$361.1M+0.3%	$357.57M+3.7%	$348.67M+8.8%	$349.39M+18.1%
Property and equipment, net	$100.93M+82.1%	$97.44M+90.6%	$84.89M+91.3%	$74.06M+91.7%	$55.42M+68.4%
Accumulated depreciation	$19.86M+39.7%	$18.3M+42.6%	$16.84M+46.7%	$15.52M+51.1%	$14.22M+54.8%
Total property and equipment, gross	$120.8M+73.5%	$115.74M+81.0%	$101.72M+82.1%	$89.58M+83.1%	$69.64M+65.5%
Operating lease right-of-use assets	$14.42M+29.2%	$14.8M+27.7%	$15.15M+27.3%	$15.5M+33.4%	$11.16M-6.7%
Goodwill	$10.7M0.0%	$10.7M0.0%	$10.7M0.0%	$10.7M0.0%	$10.7M0.0%
Intangible assets, net	$86.66M+28.9%	$88.88M-7.0%	$91.16M-8.7%	$93.43M-8.5%	$67.21M-35.6%
Deferred tax assets	$2.33M+178%	$2.34M+45.3%	$3.24M-23.2%	$3.13M—	$837K+306%
Other non-current assets	——	$20M+1,529%	$1.28M-30.0%	$1.24M-53.7%	$1.27M-26.4%
Allowance for credit losses	$0—	$0—	$0—	$0—	$0—
Equity securities	$8.13M—	$5.56M—	$8.91M—	——	——
Total assets	$547.81M+9.2%	$578.56M+8.9%	$562.79M+9.4%	$544.73M+11.8%	$501.72M+9.4%
Accounts payable	$15.04M+76.9%	$18.71M+171%	$12.21M+79.3%	$13.18M+38.2%	$8.5M-8.8%
Accrued expenses	$19.11M+7.0%	$38.29M+17.6%	$31.76M+14.8%	$24.97M+17.6%	$17.86M+21.4%
Current portion of long-term debt	$1.67M+50.0%	$417K+50.0%	$0—	$1.94M—	$1.11M—
Operating lease liabilities, current	$1.25M-12.6%	$1.33M-20.4%	$1.45M-17.0%	$1.57M+28.1%	$1.44M+20.7%
Finance Lease Liability, Current	——	——	——	——	——
Accrued interest	$1.3M—	$1.1M—	$1.2M—	——	——
Total current liabilities	$48.76M+30.8%	$68.68M+39.0%	$55.31M+24.9%	$50.89M+29.0%	$37.27M+16.6%
Long-term debt	$8.4M-5.9%	$9.64M-1.1%	$10.05M+0.3%	$8.1M—	$8.92M—
Operating lease liabilities, non-current	$25.12M+78.8%	$25.22M+75.8%	$25.3M+72.2%	$25.38M+86.0%	$14.05M+1.3%
Finance Lease Liabilities (Total)	——	——	——	——	——
Finance lease liabilities	$288K-12.2%	$314K—	$339K—	$364K—	$328K—
Total liabilities	$86.39M+40.7%	$107.68M+42.8%	$95.74M+30.2%	$89.35M+40.9%	$61.41M+9.6%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	$30K+3.4%	$30K+7.1%	$29K+3.6%	$29K+3.6%	$29K+3.6%
Additional paid-in capital	$700.26M+5.1%	$694.86M+6.0%	$688.73M+5.9%	$676.76M+6.4%	$666.12M+6.8%
Retained earnings	-$238.81M-5.7%	-$224.28M-12.1%	-$221.95M-5.8%	-$221.45M-4.5%	-$225.97M-2.3%
Accumulated other comprehensive income (loss)	-$63K-148%	$267K+16.1%	$240K-49.3%	$39K+123%	$131K+218%
Total stockholders' equity	$461.42M+4.8%	$470.87M+3.3%	$467.05M+5.9%	$455.38M+7.4%	$440.31M+9.4%
Total liabilities and stockholders' equity	$547.81M+9.2%	$578.56M+8.9%	$562.79M+9.4%	$544.73M+11.8%	$501.72M+9.4%
Allowance for Doubtful Accounts	$0—	$0—	$0—	$0—	$0—
Allowance for Doubtful Accounts Receivable (Current)	$0—	$0—	$0—	$0—	$0—
Available For Sale Securities Debt Securities Current	$184.19M+0.5%	$171.63M+1.0%	$187.5M+1.4%	$184.81M+6.1%	$183.33M+17.3%
Short- term Investments	$197.92M—	$182.78M—	$201.99M—	——	——
Accumulated Goodwill Impairment Losses	$0—	$0—	$0—	$0—	$0—
Deferred Tax Assets and Other Non-Current Assets	$4.28M+238%	$3.77M+207%	$1.28M-30.0%	$1.24M-53.7%	$1.27M-26.4%
Equipment Installment Plan Receivables (Non-Current), Net	——	——	——	——	——
Finite Lived Intangible Assets - Gross	$154.06M+22.4%	$154.06M+22.4%	$154.06M+22.4%	$154.06M+22.4%	$125.88M0.0%
Goodwill and Intangible Assets, Net	$97.35M+25.0%	$99.57M-6.3%	$101.85M-7.9%	$104.13M-7.7%	$77.9M-32.3%
Allowance for Credit Losses on Held-to-Maturity Securities	——	——	——	——	——
Long-term receivables, net	$1.92M+92.1%	$1.88M+105%	$2.05M+85.4%	$1.13M+0.6%	$1M-5.3%
Net Investment in Lease	$14.42M+29.2%	$14.8M+27.7%	$15.15M+27.3%	$15.5M+33.4%	$11.16M-6.7%
Intangible assets — net	$86.66M+28.9%	$88.88M-7.0%	$91.16M-8.7%	$93.43M-8.5%	$67.21M-35.6%
Goodwill and intangible assets, net	$97.35M+25.0%	$99.57M-6.3%	$101.85M-7.9%	$104.13M-7.7%	$77.9M-32.3%
Long-term financing receivables (net of allowances of $27 in 2026 and $34 in 2025)	——	——	——	——	——
Operating lease right-of-use assets	$14.42M+29.2%	$14.8M+27.7%	$15.15M+27.3%	$15.5M+33.4%	$11.16M-6.7%
Other non-current assets	$4.28M+238%	$3.77M+207%	$1.28M-30.0%	$1.24M-53.7%	$1.27M-26.4%
Property, plant and equipment, net	$100.93M+82.1%	$97.44M+90.6%	$84.89M+91.3%	$74.06M+91.7%	$55.42M+68.4%
Operating Lease Right-of-Use Assets in Other Assets	$14.42M+29.2%	$14.8M+27.7%	$15.15M+27.3%	$15.5M+33.4%	$11.16M-6.7%
Software and Technology Licenses, Net	$4.28M+238%	$3.77M+207%	$1.28M-30.0%	$1.24M-53.7%	$1.27M-26.4%
Accrued Manufacturing Costs	$19.11M+7.0%	$38.29M+17.6%	$31.76M+14.8%	$24.97M+17.6%	$17.86M+21.4%
Compensation and benefits	$19.11M+7.0%	$38.29M+17.6%	$31.76M+14.8%	$24.97M+17.6%	$17.86M+21.4%
Professional Service Fees Payable	$4.01M+19.4%	$3.21M+37.4%	$3.41M0.0%	$2.99M+14.4%	$3.36M-0.1%
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	$134K-20.2%	$143K-19.2%	$151K—	$160K—	$168K—
Long-Term Debt - Fair Value	——	——	——	——	——
Other Accounts Payable and Accrued Liabilities	$1.34M+14.1%	$2.13M+175%	$1.6M+150%	$869K-9.0%	$1.17M+53.0%
Total debt	$36.72M+42.1%	$37.02M+40.0%	$37.14M+38.9%	$37.35M+48.3%	$25.84M+3.2%
Total Carrying Value of Debt	$10.2M0.0%	$10.2M0.0%	$10.2M—	$10.2M—	$10.2M—
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	30.3M+5.0%	29.7M+4.2%	29.2M+4.2%	29M+4.6%	28.8M+4.6%
Common Stock Shares Outstanding	——	——	——	——	——
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M0.0%	10M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Cumulative Gross Losses and Impairments	$0—	$0—	$0—	$0—	$0—
Number of Exercisable Options	——	——	——	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	2.7M-7.5%	2.8M-6.9%	2.9M-5.3%	2.9M-7.9%	3M-6.5%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	$36.71+1.3%	$36.53+0.8%	$36.19+0.3%	$36.27+2.0%	$36.25+2.0%
Accrued Bonuses Current And Noncurrent	$7.9M+3.9%	$28.1M+20.6%	$21.8M+21.8%	$15M+19.3%	$7.6M+15.6%
Clinical studies	$2.72M+6.1%	$2.67M+3.6%	$2.42M-20.0%	$2.2M-25.2%	$2.56M+9.3%
Professional service fees	$4.01M+19.4%	$3.21M+37.4%	$3.41M0.0%	$2.99M+14.4%	$3.36M-0.1%
Accounts Receivable, Allowance for Credit Loss	$0—	$0—	$0—	$0—	$0—
Contingent liabilities	$1M—	——	——	——	——
Asset Acquisition Contingent Consideration Liability Noncurrent	$1.5M—	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%
Common stock, shares issued (in shares)	$30.3M+5.0%	$29.69M+4.2%	$29.16M+4.2%	$28.98M+4.6%	$28.84M+4.6%
Common Stock, Shares, Outstanding	$30.3M+5.0%	$29.69M+4.2%	$29.16M+4.2%	$28.98M+4.6%	$28.84M+4.6%
Long-term debt, gross	$10.2M0.0%	$10.2M0.0%	$10.2M—	$10.2M—	$10.2M—
Debt Instrument, Fair Value Disclosure	——	——	——	——	——
Less: net unamortized discount	$134K-20.2%	$143K-19.2%	$151K—	$160K—	$168K—
Debt Securities, Available-for-Sale, Allowance for Credit Loss	$0—	$0—	$0—	$0—	$0—
Debt Securities, Held-to-Maturity, Allowance for Credit Loss	——	——	——	——	——
Deferred income taxes	$2.33M+178%	$2.34M+45.3%	$3.24M-23.2%	$3.13M—	$837K+306%
Unrecognized compensation cost related to non-vested awards	——	——	——	——	——
ESPP contributions	$296K—	——	——	——	——
Current maturities of long-term debt	——	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$67.41M+14.9%	$65.18M+115%	$62.91M+142%	$60.63M+155%	$58.67M+173%
Gross Carrying Amount	$154.06M+22.4%	$154.06M+22.4%	$154.06M+22.4%	$154.06M+22.4%	$125.88M0.0%
Goodwill accumulated impairment losses	$0—	$0—	$0—	$0—	$0—
Weighted-average cash coupon (percentage)	——	——	——	——	——
Long Term Debt, Principal	——	——	——	——	——
2026	——	——	——	——	——
2027	——	——	——	——	——
2028	——	——	——	——	——
Other accrued liabilities	$10.69M+27.7%	$8.94M+11.8%	$8.89M+10.1%	$8.22M+10.4%	$8.37M+24.1%
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Insurance Reserve, Current	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$2.74M-7.5%	$2.78M-6.9%	$2.88M-5.3%	$2.91M-7.9%	$2.97M-6.5%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$36.71+1.3%	$36.53+0.8%	$36.19+0.3%	$36.27+2.0%	$36.25+2.0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Castle Biosciences.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Castle Biosciences's total assets?: Castle Biosciences (CSTL) holds $547.8M in total assets, up 9.2% year over year.
How much debt does Castle Biosciences have?: Castle Biosciences carries $36.7M in total debt against $461.4M of shareholders' equity, a debt-to-equity ratio of 0.08.
How much cash does Castle Biosciences have?: Castle Biosciences holds $63.8M in cash and equivalents.
Can Castle Biosciences cover its short-term obligations?: Its current ratio is 6.75 — current assets exceed current liabilities.
Where does Castle Biosciences's balance sheet data come from?: Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.